Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

What Was Tested

This registered phase 1, phase 2 trial tested Semaglutide.

This study is a multicenter, randomized, controlled study.

A sample size of 240 cases is proposed to be included.

It had two arms (groups): Semaglutide group: patients receive semaglutide treatment. (experimental) and Oral medication group: patients receive triple hypoglycemic oral medications. (active comparator).

The registry classes the interventions as drug.

Who Took Part

The registry lists 240 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients with newly diagnosed type 2 diabetes. Age between 18 and 65 years old.

The full record lists 3 inclusion and 4 exclusion criteria; among the exclusions: type 1 diabetes; elevated creatinine or urinary albumin/creatinine; combined with coronary heart disease, tumor or pregnancy.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2025-06-01 with completion listed for 2026-05-31.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Diabetes remission rate (time frame: From enrollment to the end of follow-up at 11 months).

It also tracked 3 secondary outcomes, for example HbA1c, Hypoglycemia rate and Adverse reactions.

What This Means in Plain Language

Put simply, this is a phase 1, phase 2, randomized trial of Semaglutide in 240 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.